Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin Lesions: Histologic, Immunohistologic, and Molecular Biology Findings  by Asadullah, Khusru et al.
Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin
Lesions: Histologic, Immunohistologic, and Molecular
Biology Findings
Khusru Asadullah,* Markus Friedrich,* Sandra Hanneken,* Christoph Rohrbach,* Heike Audring,*
Athanasios Vergopoulos, Merle Ebeling,* Wolf-Dietrich DoÈcke, Hans-Dieter Volk, and Wolfram Sterry*
Institute of Medical Immunology and *Department of Dermatology, University Hospital ChariteÂ, Berlin Humboldt University, Berlin, Germany
Interleukin-10 is an important anti-in¯ammatory and
immunosuppressive cytokine with major impact on
several immune reactions, including regulatory
mechanisms in the skin. Recently, we performed a
phase II trial in psoriatic patients receiving subcuta-
neously interleukin-10 over 7 wk. The clinical
response suggested that interleukin-10 might repre-
sent a novel anti-psoriatic drug. In order to under-
stand better the mode of action and to elucidate the
effects of systemic interleukin-10 treatment on the
skin immune system, skin punch biopsies from sites
different from interleukin-10 injection were ana-
lyzed. Biopsies were obtained from the patients
before, at the end, and 3 wk after interleukin-10
therapy. The results are reported here. Histologic
examination showed a decrease of several parameters
re¯ecting the psoriatic disease activity as acanthosis
and extension of the horny layer. Immunohistologic
examination demonstrated decreasing numbers of
in®ltrating T cells, dermal CD1a+ cells, and a dimin-
ished proliferation of epidermal cells. Using a novel,
quantitative reverse transcriptase±polymerase chain
reaction approach a signi®cant shift within the cyto-
kine pattern was found. Interleukin-10 therapy led to
a decrease of cutaneous interleukin-8 and interleu-
kin-10 mRNA expression. Whereas no signi®cant
changes of interleukin-6, tumor necrosis factor-a,
and interferon-g expression were found, interleukin-4
was strongly upregulated suggesting a shift from a
type 1 towards a type 2 cytokine pattern. The
changes within the local cytokine pattern seem to be
disease-related, as an inverse course was found in a
single interleukin-10 nonresponding patient. Our
®ndings demonstrate considerable effects of systemic
interleukin-10 application on the skin immune
systems, which might contribute to the anti-psoriatic
activity of interleukin-10. Key words: cytokines/
immunotherapy/interleukin-10/psoriasis. J Invest Dermatol
116:721±727, 2001
I
n 1989, Mosmann and coworkers observed the production
of a so-called ``cytokine synthesis inhibitory factor'' by T
helper 2 cell clones (Fiorentino et al, 1989). This factor was
later included in the current cytokine nomenclature as
interleukin (IL)-10. Today we know that IL-10 is produced
by a variety of cells, in particular monocytes, macrophages, B cells,
and T cell subsets (De Waal Malefyt et al, 1991a; Spits and De Waal
Malefyt, 1992; D'Andrea et al, 1993; Asadullah et al, 1999a).
Numerous in vitro and animal experiments demonstrated the great
impact of IL-10 on immunoregulation. It promotes the develop-
ment of a type 2 cytokine pattern by inhibiting the interferon (IFN)
-g production of T lymphocytes, particularly via the suppression of
IL-12 synthesis in accessory cells (D'Andrea et al, 1993), as well as
the proin¯ammatory cytokine production and antigen-presenting
capacity of antigen-presenting cells (APC) (De Waal Malefyt et al,
1991b; Fiorentino et al, 1991).
Owing to this considerable anti-in¯ammatory and immunosup-
pressive capacities, recombinant human IL-10 became a candidate
for the therapy of several immune diseases as Crohn's disease (Van
Deventer et al, 1997), transplant rejection (Wissing et al, 1997), and
recently psoriasis. In a pilot trial we observed considerable clinical
effects in the two out of three psoriatic patients receiving lesional,
subcutaneous IL-10 applications (Asadullah et al, 1998).
Consequently, we performed an open label phase II trial, including
10 psoriatic patients (Asadullah et al, 1999c). Patients received
subcutaneous IL-10 over a 7 wk period. The treatment was well
tolerated and systemic anti-psoriatic effects were found in nine of
10 patients. A signi®cant decrease of the psoriasis area and severity
index (PASI) from 18.1 to 9.3 was observed. Recently, Reich et al
(1998) reported a similar clinical effectiveness (decrease of the PASI
score by 67.9%) after 6 wk of IL-10 treatment. These promising
data suggest that IL-10 might represent a novel therapeutic
approach for the treatment of psoriasis. The mode of action,
however, is not fully understood (Asadullah et al, 2000).
In contrast to numerous in vitro and animal investigations, there is
only limited information on the immunologic effects of IL-10
therapy in humans. These data are mainly restricted to certain
information regarding systemic immunologic alterations (Chernoff
et al, 1995; Asadullah et al, 1998, 1999a). The systemic
immunosuppressive effects we observed (decrease of monocytic
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HLA-DR expression, IL-12 plasma levels, and responsiveness to
recall antigens) as well as a shift towards a type 2 cytokine pattern
(increasing proportion of IL-4 producing T cells, increase in IgE
serum levels) might be the basis of the anti-psoriatic activity of IL-
10 (Asadullah et al, 1998, 1999a,c, 2000). Certainly, however,
direct effects of IL-10 on the skin immune system might be
crucially involved in the anti-psoriatic mode of action as well.
In this study we analyzed the histologic, immunohistologic, and
molecular biology effects of systemic IL-10 therapy, demonstrating
signi®cant cutaneous immunomodulatory effects.
MATERIALS AND METHODS
Biopsies from IL-10-treated patients The study was approved by
the Institutional Review Board of the Medical Faculty, and written
informed consent was obtained from all patients.
Serial biopsies were obtained from 10 adult patients with moderate or
severe chronic plaque psoriasis undergoing IL-10 therapy. Patients
received subcutaneous applications of recombinant human IL-10 (SCH
52000; kindly provided by Essex Pharma, Munich, Germany/Schering
Plough Research Institute, Kenilworth, NJ) either 8 mg per kg per d
(n = 5) or 20 mg per kg three times per week (n = 5) over a period of
49 d. The treatment was well tolerated and anti-psoriatic effects were
found in nine of 10 patients. A signi®cant decrease of the PASI by
55.3 6 11.5% (mean 6 SEM) was observed (p < 0.02) (Asadullah et al,
1999c). Three skin biopsies (4 mm punch biopsies from the center of the
same plaque/region) were obtained from each of the 10 patients at each
of the following three points in time: 7 d before IL-10 therapy (day ± 6),
at day 50 (®rst day after the end of therapy) as well as day 71 (3 wk after
the end of therapy). So, altogether 90 biopsies were available for
histologic (formaldehyde), immunohistologic (snap frozen), and mol-
ecular biology (snap frozen) examination.
Histologic examination Hematoxylin±eosin staining and histologic
examination of two slices of each skin punch biopsy were performed by
an experienced senior scientist as described recently (Asadullah et al,
1999c). The histologic investigations included the evaluation of the main
psoriatic parameters such as acanthosis, hyperkeratosis, and parakeratosis,
the mitotic activity of the epidermis, papillary edema, dilation and
tortuosity of capillaries, and neutrophils in the dermis, the stratum
spinosum, as well as in the horny layer, respectively.
Immunohistochemical examination Cryostat sections (6 mm) were
made from the frozen biopsies. Two sections each were stained with
antibodies against CD3 (Clone: T3±4B5), CD4 (MT 310), CD8 (DK
Figure 1. IL-10 therapy decreased the histologic parameters for
psoriatic disease. Intralesional skin biopsy specimens were obtained
from 10 psoriatic patients before, at the end (day 50), and 3 wk after IL-
10 therapy (day 71). Number of mitoses and extension of acanthosis and
horny layer were determined by histologic examination. The values are
mean 6 SEM. *p < 0.05, **p < 0.01 vs before therapy, Wilcoxon test.
Figure 2. Reduction of epidermal thickness, hyperkeratosis, and
parakeratosis in a typical patient undergoing IL-10 therapy.
Intralesional skin biopsy specimens were obtained from a psoriatic patient
before (a), at the end (day 50, b), and 3 wk after IL-10 therapy (day 71,
c). A decrease of epidermal thickness along with a decrease of
parakeratosis and Munro's abscesses as well as a moderate reduction of
the in®ltrate is demonstrable. Hematoxylin±eosin staining, Scale bars:
20 mm (a,b) and 50 mm (c), respectively.
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25) and CD1a (NA 1/34) (all Dako, Hamburg, Germany), CD54
(ICAM-1, 84H10, Coulter-Immunotech, Krefeld/Hamburg, Germany),
and Ki67 (MIB 1, Dianova, Hamburg, Germany), respectively. They
were processed using the alkaline phosphatase and monoclonal anti-
alkaline phosphatase method as described previously (Kellner et al, 1991).
Using a 10 3 10 mm2 grating ocular (3 40 magni®cation) in a light
microscope, positive cells were counted in the epidermis and upper
dermis. Results (mean value of the two slices) were expressed as cells per
mm2.
Molecular biology examination for cytokine mRNA expression
RNA isolation and reverse transcription Skin biopsies were removed at the
time-points indicated above and immediately snap frozen in guanidinium
isothiocyanate solution. Before the analysis and during thawing tissues
were homogenized using an Ultraturrax tissue homogenizer (Jahnke and
Kunkel, Staufen, Germany). Total RNA was extracted from the biopsies
by a matrix method as recommended by the manufacturer (Dianova,
Hamburg, Germany). RNA was DNAse-digested and subsequently
reverse transcribed as previously described (Murphy et al, 1993).
Therefore, a master solution was prepared by adding 80 ml of 5 3 ®rst
strand buffer (GibcoBRL, Paisley, U.K.), 40 ml of 100 mM dithiothreitol
(GibcoBRL), 40 ml of 10 mM dNTP (Pharmacia Biotech, Uppsala,
Sweden), 20 ml of 0.1 mg per ml 5¢-pd(T)12±18-3¢ (Pharmacia Biotech),
10 ml of 40 U per ml RNasin ribonuclease inhibitor (Promega, Madison,
WI), and 20 ml of 1 U per ml RQ1 RNase-free DNAse (Promega). This
was suf®cient for 10 reactions. Twenty-one microliters of master solution
were added to about 0.6±0.8 mg of total RNA and 19 ml of DEPC
water. The mixture was incubated at 37°C for 30 min, thereafter for
5 min at 95°C. The DNAse-digested RNA was stored at ±20°C. The
reverse transcription was started by adding 1 ml of 40 U per ml RNasin
ribonuclease inhibitor (Promega) and 1 ml of 200 U per ml MMLV-
reverse transcriptase (GibcoBRL) per tube. The mixture was incubated at
room temperature for 10 min and thereafter at 37°C for 1 h. The
reaction was stopped by incubating at 95°C for 7±10 min. After synthesis
cDNA was cooled and stored at ±20°C.
Quanti®cation of gene expression by real-time polymerase chain
reaction (PCR) The expression of each gene transcript in skin
biopsies was analyzed by real-time PCR using the ABI PRISM 7700
Sequence Detection System (TaqMan, Perkin-Elmer Biosystems,
Weiterstadt, Germany). The method employs the 5¢ nuclease activity of
Taq polymerase to cleave a nonextendable hybridization probe during
the extension phase of the PCR. The approach uses dual-labeled
¯uorogenic hybridization probes. One ¯uorescence dye serves as a
reporter (FAM, 6-carboxy¯uorescein) and its emission spectrum is
quenched by the second ¯uorescent dye (TAMRA, 6-carboxy-
tetramethyl-rhodamine). The reactions are monitored in real time during
the log phase of product accumulation. The increase of the reporter dye
¯uorescence intensity during PCR is proportional to the ampli®cation of
the target sequence. The cycle number at which the ampli®cation plot
crosses a ®xed threshold above baseline is de®ned as threshold cycle (Ct).
To control variation in cDNA contents throughout different
preparations, all results are related to the concentration of a gene, whose
expression remains constant (``housekeeping gene''). Our choice of
housekeeping gene consisted in the human hypoxanthine-
phosphoribosyl-tranferase gene. To normalize the different amounts of
cDNA (DCt), we calculated the differences between the mean Ct
cytokine and the mean Ct hypoxanthine-phosphoribosyl-tranferase.
Relative quantitation was performed using the comparative DDCt
method according to the manu-facturer's instructions. By subtracting
DCtbefore therapy from DCtafter therapy, DDCt was obtained. The result for
the cytokine gene expression after treatment relative to before therapy
was given by a unit-less value through the formula 2±DDCt.
The PCR reaction was performed in a ®nal volume of 25 ml
containing 1 ml cDNA, 12.5 ml Master Mix (TaqMan Universal PCR
Master Mix, Perkin Elmer, Applied Biosystems, Weiterstadt, Germany),
1 ml hybridization probe, 6 ml primer mix, and 5.5 ml distilled water.
After an initial step of 2 min at 50°C involving activation of uracyl-n-
glycosylase and degradation of any pre-existing contaminating RNA
sequences, a denaturation and a hot start for AmpliTaq Gold DNA
polymerase (Perkin Elmer Biosystems) was performed at 95°C for
10 min. The ampli®cation took place in a two-step PCR (40 cycles;
15 s denaturation step at 95°C and 1 min annealing/extension step at
60°C). The mean Ct values for hypoxanthine-phosphoribosyl-tranferase
and the cytokines were calculated from double determinations.
Statistical analysis Data are presented as mean 6 SEM. Statistical
analysis was performed using the Wilcoxon test for paired values and the
Pearson's coef®cient with two-tailed signi®cance levels for correlation
analyses. Differences were considered signi®cant at p < 0.05. As the
number of patients in the two different dose schedules was small (®ve
patients per group) no statistical comparison between the groups was
performed.
RESULTS
Histologic ®ndings Histologically, a decrease of epidermal
thickness along with a decrease of parakeratosis and the number
of mitoses were observed. Figure 1 shows the mean values of these
objectively determined parameters. Moreover, the quantity of the
in®ltrate, including both granulocytes and mononuclear cells as
well as the Munro's abscesses decreased, whereas the morphology
of the papillary vessels was the same as before. Figure 2 shows
typical histologic changes in a single patient. So, overall evaluation
of the main psoriatic parameters clearly indicated decreasing disease
activity under IL-10 therapy in eight of 10 patients. These data
correspond to our clinical ®ndings (Asadullah et al, 1999c).
Immunohistochemical ®ndings A considerable decrease in the
number of CD3+ lymphocytes (in®ltrating T cells) and CD1a+ cells
(cutaneous APC) was observed. The T cell in®ltration showed a
clear correlation with the decreasing PASI score (r = 0.72; p
< 0.001). Moreover, the number of Ki67-positive epidermal cells
Figure 3. IL-10 therapy decreased cutaneous T cell in®ltration,
dermal ICAM-1 and CD1a expression, and epidermal proliferative
activity (Ki67). Intralesional skin biopsy specimens were obtained from
10 psoriatic patients before, at the end (day 50), and 3 wk after IL-10
therapy (day 71). By immunohistologic examination (alkaline phosphatase
and monoclonal anti-alkaline phosphatase technique) the numbers of
positive cells per mm2 were determined for Ki67 (MIB1) (epidermis),
CD54 and CD1a (dermis), and CD3 (both compartments). Data are
shown as mean 6 SEM. *p < 0.05 vs before therapy, Wilcoxon test.
Table I. Immunohistologic ®ndings during IL-10 therapya
Marker
No. of positive cells per mm2
Before
therapy
At the end of
therapy
(day 50)
3 wk post-
treatment
day 71
CD3
Epidermis 106 6 15 104 6 19 91 6 17
Dermis 381 6 48 242 6 55b 264 6 68
CD4
Epidermis 77 6 11 106 6 17 73 6 9
Dermis 259 6 48 193 6 32 241 6 40
CD8
Epidermis 56 6 10 55 6 10 48 6 8
Dermis 148 6 30 91 6 19 105 6 20
aData are mean 6 SEM from the 10 patients.
bp < 0.05 vs before therapy, Wilcoxon test
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declined signi®cantly, indicating a decreasing keratinocyte
proliferation. The expression of the adhesion molecule ICAM-1
(CD54) was detectable on basal keratinocytes above the dermal
papillae before therapy and cleared during therapy. Moreover, a clear
decreasing number of mononuclear CD54+ cells was found in the
dermis (Figs 3 and 4). When investigating whether the signi®cant
decrease in the number of in®ltrating T cells results from an effect on
a certain subpopulation, no preferential decrease of either CD4+ or
CD8+ cells was found (Table I). Remarkably, in the single patient,
who did not respond clinically to IL-10 therapy, no decline in T cell
in®ltration of lesions was measured and increasing numbers of
dermal CD1a+, CD54+ cells were observed. Moreover, the number
of proliferating epidermal cells (Ki67+ keratinocytes) increased
during the treatment period in this patient (data not shown).
Molecular biology ®ndings The course of the cutaneous
cytokine mRNA expression is shown in Fig 5. A remarkable shift
within the cytokine pattern was observed. The most obvious change
was the considerable (5±6-fold) increase in the expression of the Th2
cytokine IL-4. So, a signi®cantly higher IL-4 gene expression level
was found at the end of therapy (p = 0.015). Remarkably, the
enhanced IL-4 expression persisted even 3 wk after the end of
therapy (p = 0.05) (Fig 5). In contrast, the typical Th1 cytokine
IFN-g was almost constantly expressed. This, however, resulted in a
long-lasting shift within the immunologic important Th1/Th2
balance (Fig 6). The shift from a Th1 toward a Th2 pattern on the
local level corresponds well to the same systemic effect of IL-10
therapy we recently described (Asadullah et al, 1998). Moreover, a
signi®cant decrease of cutaneous IL-8 mRNA levels was found.
Figure 4. Immunohistologic changes in a typical patient. Four millimetres punch biopsies were obtained from lesional skin of a patient before
(left column), at the end (day 50, middle column), and 3 wk after IL-10 therapy (day 71, right column). Immunohistochemical staining was performed
using the alkaline phosphatase and monoclonal anti-alkaline phosphatase technique and antibodies against CD3 (a±c), CD54 (d±f), Ki67 (g±i), and CD1a
(j±l). Scale bars: 20 mm.
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A decrease in the IL-10 mRNA expression was observed. No
signi®cant changes were found with respect to the cutaneous IL-6
and tumor necrosis factor (TNF) -a expression (Fig 5).
In order to estimate whether the changes within the cytokine
pattern might be associated with the clinical response to therapy,
the course of a single nonresponder was compared with that of the
other patients who responded well. The nonresponding patient was
clinically indistinguishable from the other patients before IL-10
therapy. As in the other patients the biopsies were obtained from
always the same site (center of an established plaque). Remarkably,
this patient, who showed further progress in disease activity during
and in particular after IL-10 therapy, exhibited a different
cutaneous cytokine expression pattern compared with that of the
other patients. In contrast to the other patients, high IL-10 and low
IFN-g, IL-6, and IL-8 expression was found before therapy
(Table II). Moreover, during IL-10 therapy the cytokine pattern
was inverse to that of the responders: IL-4 decreased (undetectable
at the end of therapy), whereas IL-8 slightly increased (data not
shown).
DISCUSSION
Our investigations demonstrate considerable effects of systemic IL-
10 application on the skin immune system, which might contribute
to the anti-psoriatic activity of IL-10 therapy. Beside our previous
observation that IL-10 therapy suppresses the cutaneous delayed
type hypersensitivity response (Asadullah et al, 1998, 1999c), this is
the ®rst report on this immunomodulatory capacity of IL-10 in
humans.1
The histologic (extension of acanthosis and horny layer,
frequency of mitosis) and immunohistologic ®ndings (number of
in®ltrating T cells and proliferating keratinocytes) demonstrated a
decrease in parameters typical for the psoriatic disease activity. This
supports the clinical observation of bene®cial effects of IL-10
therapy in psoriasis. It is unlikely, however, that IL-10 exerts its
anti-psoriatic activity via direct effects on keratinocytes. In fact,
using corresponding concentrations of recombinant human IL-10
as detectable in plasma during IL-10 therapy, we recently
demonstrated an IL-10 nonresponsiveness of activated fresh
human keratinocytes as well as HaCaT cells in vitro: neither effects
on cytokine formation, surface molecule expression nor on
proliferation were observed (Seifert et al, 2000).
It is likely that IL-10 exerts its anti-psoriatic activity by effects on
different immune cell populations present within the skin as well as
in the circulation. This in particular includes T cells and APC and
their interactions. Psoriasis is regarded as a T cell-dependent
(auto)immune disease (Valdimarsson et al, 1986; Christophers and
Sterry, 1993), probably initiated by presentation of so far unknown
``psoriasis-related antigens'' by specialized cutaneous APC
Figure 5. Intralesional increase of IL-4
mRNA expression and reduction of IL-8 and
IL-10 expression in psoriatic patients
undergoing IL-10 therapy. Intralesional skin
biopsy specimens were obtained from 10 psoriatic
patients before, at the end (day 50), and 3 wk
after IL-10 therapy (day 71). The cytokine
expression levels were determined by quantitative
real-time TaqManâ reverse transcriptase±PCR.
The relative expression levels were calculated in
relation to the pretreatment values (DDCt) as
described in Materials and methods and are shown
as mean 6 SEM. *p < 0.05 vs before therapy,
Wilcoxon test.
Figure 6. IL-10 induced a shift within the cutaneous type 1/type
2 cytokine balance. Intralesional skin biopsy specimens were obtained
from 10 psoriatic patients before, at the end (day 50), and 3 wk after IL-
10 therapy (day 71). The ratios of the single IFN-g/IL-4 expression
values were calculated. The individual pretreatment levels were
considered to be 1. Data are shown as mean 6 SEM. *p < 0.05 vs
before therapy, Wilcoxon test.
Table II. Comparison of the pretreatment cytokine
expression values between responders vs the single
nonresponding patienta
Responder
(n = 9)
Nonresponder
(n = 1)
IFN-g 2.6 6 0.8 0.91
IL-4 1.3 6 0.9 0.55
IL-6 20.2 6 7.1 8.6
IL-8 1200 6 1004 230
TNF-a 90 6 1.6 100
IL-10 3.6 6 0.92 6.5
aData are mean 6 SEM of the DCt values (3 1000).
1After typesetting of this paper, a manuscript was published describing
similar effects of IL-10, as reported here (Reich et al, 2001).
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(Weinstein, 1996; Norris et al, 1997). IL-10 is able to suppress the
APC activity of monocytes/macrophages and dendritic cells (De
Waal Malefyt et al, 1991a,b; Fiorentino et al, 1991; Enk and Katz,
1993; Mitra et al, 1995). In fact, depressed HLA-DR and CD86
expression as well as TNF-a and IL-12 secretion capacity of
circulating peripheral blood monocytes were observed during IL-
10 therapy (Asadullah et al, 1998). Although the functional impact
of IL-10 treatment on single leukocyte subpopulations present
within the skin could not be investigated, here we observed
decreasing numbers of APC (CD1a+) and in®ltrating T cells
(CD3+). This might be both just a secondary consequence of the
decreasing disease activity, i.e., an epiphenomenon, or the
re¯ection of a direct IL-10 effect leading to a different behavior
of these immune cells (including a distinct homing), crucial for the
mode of action.
Recently, we found that IL-10 administration in¯uences the
peripheral T cell subpopulations with regard to their ex vivo
cytokine production (Asadullah et al, 1998). By using a novel real-
time reverse transcriptase±PCR approach in order to quantify the
mRNA expression of several cytokines simultaneously and more
precisely, here we found a remarkable shift within the cutaneous
cytokine pattern. IL-10 strongly and long-lastingly induced the
cutaneous expression of the type 2 cytokine IL-4. In contrast, no
effect on cutaneous IFN-g expression (type 1) was observed. This
resulted in a persistent shift of the immunologic important type 1/
type 2 cytokine balance on local level, corresponding well to the
systemic effects of IL-10 therapy we described before (Asadullah et al,
1998). According to the predominant expression of IL-2 and IFN-g
and the lack/low-level expression of IL-4 in skin lesions, psoriasis is
characterized by a type 1 cytokine pattern (Uyemura et al, 1993;
Schlaak et al, 1994). As this immunologic imbalance is considered to
be of critical importance in psoriasis (Nickoloff, 1991; Krueger et al,
1990; Asadullah et al, 1999b), the IL-10-induced shift from a type 1
toward a type 2 pattern on the local level might have contributed to
the anti-psoriatic effects of IL-10. This corresponds well to the
depressed delayed type hypersensitivity reaction in our patients
during therapy, as this reaction is considered to be mediated by type
1 cytokines (Asadullah et al, 1998, 2000). Moreover, similar to that
what we found during systemic IL-10 therapy, very recently Walters
and coworkers2 reported that successful ultraviolet therapy of
psoriasis is associated with a considerable increase of cutaneous IL-4
expression. It can be speculated that IL-4 induction is a common
phenomenon of different anti-psoriatic therapies and, therefore, it
should be considered to use this cytokine itself for the therapy of
psoriasis.
Finally, the signi®cant depression of the IL-8 mRNA expression
might have contributed to the anti-psoriatic activity of IL-10
therapy. IL-8 is a potent proin¯ammatory cytokine considered to
be a crucial mediator in psoriasis. It is overexpressed in untreated
psoriasis, acting as a chemoattractant, in particular, for granulocytes
cumulating in psoriatic lesions (Gillitzer et al, 1991; Lemster et al,
1995; Kulke et al, 1996). A recent report has indicated therapeutic
effects of anti-IL-8 antibody therapy in psoriasis.3 In contrast to
evidences from our IL-10 pilot trial (Asadullah et al, 1998) we
found a decrease of the cutaneous IL-10 mRNA expression. This
might result from the auto-downregulating capacity of IL-10. No
signi®cant effects of systemic IL-10 application on cutaneous TNF-
a and IL-6 expression were found. These ®ndings argue against the
hypothesis that IL-10 exerts its anti-psoriatic activity by restoring
the endogenous IL-10 production or by a broad anti-in¯ammatory
mode, suppressing proin¯ammatory cytokine expression in general.
The stringent correlation of the changes in cytokine expression
pattern (increase of IL-4 and decrease of IL-8 expression) and a
bene®cial clinical and histologic course of psoriasis supports their
pathophysiologic relevance. The fact that an inverse course of IL-4
and IL-8 expression was observed in the single patient who did not
respond to therapy supports this view. Moreover, a different
pretreatment cytokine pattern (no IL-10 de®ciency, lower expres-
sion of proin¯ammatory cytokines) indicates that this particular
patient might suffer from an immunologically distinct type of
psoriasis. Further investigations are necessary to determine whether
the individual cutaneous cytokine pattern predicts the response to
IL-10 therapy.
Our data demonstrate a strong regulatory impact of systemic IL-
10 application on the skin immune system. The observed effects
offer an explanation for the anti-psoriatic activity of IL-10. Further
investigations are necessary to elucidate whether they result from
targeting skin immune cells or noncutaneous cells (e.g., circulating
immune cells) secondary in®ltrating the skin. Moreover, it has to be
determined which particular IL-10 effects are crucial for the anti-
psoriatic activity. This may lead to even more focused novel
therapeutic approaches.
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